Binimetinib

Binimetinib
Systematic (IUPAC) name

5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide
Clinical data
Trade names	Binimetinib
Legal status	Investigational
Identifiers
CAS Number	606143-89-9
ATC code	None
PubChem	CID 10288191
ChemSpider	8463660
Chemical data
Formula	C₁₇H₁₅BrF₂N₄O₃
Molar mass	441.23 g/mol
SMILES CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
InChI InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26) Key:ACWZRVQXLIRSDF-UHFFFAOYSA-N

Binimetinib (MEK162, ARRY-162) is a MEK inhibitor being developed by Array Biopharma. It is currently in phase 3 clinical trials for ovarian cancer, BRAF mutant melanoma, and NRAS mutant melanoma. ^[1]

References

↑ "Array biopharma:: Binimetinib"

Targeted therapy / extracellular chemotherapeutic agents/antineoplastic agents (L01)

CI monoclonal antibodies ("-mab")

Receptor tyrosine kinase	ErbB: HER1/EGFR (Cetuximab Panitumumab) HER2/neu (Trastuzumab Trastuzumab emtansine)

Others for solid tumors	EpCAM (Catumaxomab Edrecolomab) VEGF-A (Bevacizumab)

Leukemia/lymphoma	lymphoid: CD20 (Ibritumomab Ofatumumab Rituximab Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) myeloid: CD33 (Gemtuzumab)

Tyrosine-kinase inhibitors ("-nib")

Receptor tyrosine kinase	ErbB: HER1/EGFR (Erlotinib Gefitinib Vandetanib) HER1/EGFR and HER2/neu (Afatinib Lapatinib Neratinib) RTK class III: C-kit and PDGFR (Axitinib Masitinib Pazopanib Sunitinib Sorafenib Toceranib) FLT3 (Lestaurtinib) VEGFR (Axitinib Cediranib Lenvatinib Nintedanib Pazopanib Regorafenib Semaxanib Sorafenib Sunitinib Tivozanib Toceranib Vandetanib) RET inhibitors: Vandetanib (Also VEGFR and EGFR). c-MET inhibitor: Cabozantinib (Also VEGFR2).

Non-receptor	bcr-abl (Imatinib Dasatinib Nilotinib Ponatinib) Src (Bosutinib) Janus kinase (Lestaurtinib Ruxolitinib Pacritinib) MAP2K (Cobimetinib Selumetinib Trametinib Binimetinib) EML4-ALK (Ceritinib Crizotinib) Bruton's (Ibrutinib)

Other

fusion protein against VEGF (Aflibercept)
proapoptotic peptide against ANXA2 and prohibitin (Adipotide)
exotoxin against IL-2 (Denileukin diftitox)
mTOR inhibitors
- Everolimus
- Temsirolimus
hedgehog inhibitors
- Sonidegib
- Vismodegib
CDK inhibitor (Palbociclib)

This article is issued from Wikipedia - version of the Thursday, December 17, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.